The Hidden Biological Cost of CEO Performance

By Dr. Denis Cronson

The numbers may still look strong. Boards and investors may not recognize the decline.

But decades of research reveals a sobering fact: CEOs can continue to deliver results even while their capacity behind judgment, emotional regulation and decision-making is already deteriorating. 

By the time the damage becomes visible in their leadership, the consequences can extend far beyond the executive, putting teams, strategic decisions and entire organizations at risk. To understand why this decline can go unnoticed, we must look beyond performance metrics and examine the biological systems that sustain it. For 20 years, I have studied what high performance looks like inside the body. I have run blood panels, psychological profiles, hormonal and nutritional diagnostics, sleep assessments, and functional cognition tests on people whose careers depend on their ability to keep performing under pressure.

That experience has taught me something uncomfortable: the people we trust to lead organizations may not always be the best judges of when their capacity has begun to change.

In leadership, we imagine that our bodies will tell us when we have gone too far. They do, but rarely in language strong enough to defeat ambition. 

The brain does not receive a precise readout of remaining capacity. It relies on interoception: the process by which the nervous system detects, and the brain interprets, signals arising from within the body. These include sleepiness, tension, pain, hunger, agitation, slowing, and fatigue.

But these signals do not come with instructions. Fatigue might mean stop, but it can also mean this matters.

Irritability might indicate declining regulation. It can also feel like justified impatience with people who are moving too slowly.

A loss of curiosity might reflect cognitive narrowing. To the person experiencing it, it may feel like clarity. But according to my research and many others’, a leader who can’t access emotional bandwidth or creative range because of physiological debt makes decisions with a narrower, risk-averse lens.

A neuroscience framework called predictive coding helps explain this. The brain uses past experience to anticipate what a signal means. For successful leaders, years of performing under pressure have built a particularly powerful prediction: something along the lines of, “I have handled worse.”

Every previous success under pressure strengthens the prediction. The leader keeps delivering, so continued output becomes evidence that continued strain is safe.

In most professions, declining capacity eventually produces external feedback. Corporate culture can reward availability, endurance and results. Executives who work through fatigue may be praised for their commitment. But, the biological costs remain invisible. 

This is not an argument against high performance or a case for shrinking ambition. It is an argument that continued performance is an imperfect measure of remaining capacity.

The question for every CEO and boards that oversee them is not whether a leader can keep performing, but whether the biological foundations of that performance remain sustainable. 

There is a last moment when stepping back is still a decision.

After that, you are no longer the decision maker.

About Dr. Denis Cronson

Dr. Denis Cronson is a physician–strategist in Zug, Switzerland, redefining leadership through the biology of performance. With surgical training and an MBA (cum laude), he has spent over 30 years bridging medical science and corporate strategy, advising multinationals on enterprise health design, executive frameworks, and pandemic resilience. His most recent release, “The Executive Condition: The Hidden Health Crisis of High-Performing Leaders,” is now available.